DuBrock Hilary M, Salgia Reena J, Sussman Norman L, Bartolome Sonja D, Kadry Zakiyah, Mulligan David C, Jenkins Sarah, Lackore Kandace, Channick Richard N, Kawut Steven M, Krowka Michael J
Department of Medicine, Mayo Clinic, Rochester, MN.
Department of Medicine, Henry Ford Hospital, Detroit, MI.
Transplant Direct. 2019 May 22;5(6):e456. doi: 10.1097/TXD.0000000000000900. eCollection 2019 Jun.
The role of liver transplantation (LT) in the management of portopulmonary hypertension (POPH) is poorly understood. The aim of this study was to better understand provider attitudes and practice patterns regarding the management of patients with POPH and to assess the concordance between clinical practice and current guidelines.
We performed a multicenter survey study of hepatologists and pulmonary hypertension (PH) physicians at US LT centers that performed >50 transplants per year. Survey responses are summarized as number (%). Associations were assessed using a Wilcoxon-rank sum, chi-square, or Fisher exact test, as appropriate.
Seventy-four providers from 35 centers were included. There was marked variability regarding screening practices, management, and attitudes. Forty-two percent responded that POPH nearly always or often improves with LT, and 15.5% reported that POPH rarely or never improves. In contrast to current guidelines, 50.7% agreed that treated POPH should be an indication for LT in patients with compensated cirrhosis. Hepatologists were more likely than PH physicians to agree that POPH should be an indication for LT ( = 0.02). Forty-nine percent of respondents thought that the current POPH Model for End-stage Liver Disease exception criteria should be modified, and management of patients with an elevated mean pulmonary arterial pressure and normal pulmonary vascular resistance differed from current policies.
There is marked variability in provider attitudes and practice patterns regarding the management of POPH. This study highlights the need for prospective studies to inform practice and for improved implementation of practice guidelines in order to standardize care.
肝移植(LT)在门肺高压(POPH)管理中的作用尚不清楚。本研究的目的是更好地了解医疗服务提供者对POPH患者管理的态度和实践模式,并评估临床实践与当前指南之间的一致性。
我们对美国每年进行超过50例移植手术的肝移植中心的肝病学家和肺动脉高压(PH)医生进行了一项多中心调查研究。调查结果以数量(%)进行总结。根据情况,使用Wilcoxon秩和检验、卡方检验或Fisher精确检验评估相关性。
纳入了来自35个中心的74名医疗服务提供者。在筛查实践、管理和态度方面存在显著差异。42%的受访者表示,POPH在肝移植后几乎总是或经常改善,15.5%的受访者表示POPH很少或从不改善。与当前指南相反,50.7%的受访者同意,对于代偿期肝硬化患者,经治疗的POPH应作为肝移植的指征。肝病学家比PH医生更有可能同意POPH应作为肝移植的指征(P = 0.02)。49%的受访者认为应修改当前的终末期肝病模型中POPH的例外标准,并且对平均肺动脉压升高而肺血管阻力正常的患者的管理与当前政策不同。
医疗服务提供者对POPH管理的态度和实践模式存在显著差异。本研究强调需要进行前瞻性研究以指导实践,并改进实践指南的实施,以规范治疗。